Analysts at Oppenheimer provided their comments on Incyte Corporation (NASDAQ:INCY) ahead of the company’s Q3 results, highlighting several key topics, including the Jakafi script analysis and recent company updates. The brokerage’s analysis of Symphony script data showed Jakafi volume in Q3 had around 10% TRx growth over Q2 and it estimates Jakafi Q3 sales at $567 million.

According to the analysts, the company achieved key milestones in Q2, including the dual approvals of topical rux (Opzelura) in AD and Jakafi in cGVHD, although the debut of Opzelura was complicated by the black box warning. More recently, the company presented full results from the Ph3 TRuE-V program of Opzelura in vitiligo at EADV21 with US/ EU filings on the horizon.

The analysts believe the company’s diverse pipeline should drive accelerating revenue growth, which they believe is currently undervalued.